ALGS Aligos Therapeutics Inc.

18
-1.12  -6%
Previous Close 19.12
Open 19.13
52 Week Low 12.82
52 Week High 22.5
Market Cap $664,023,348
Shares 36,890,186
Float 33,737,187
Enterprise Value $603,065,920
Volume 65,541
Av. Daily Volume 0
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
ALG-000184
Hepatitis B
Phase 1
Phase 1
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.

Drug Pipeline

Drug Stage Notes
ALG-01013
Hepatitis B
Phase 1
Phase 1
Phase 1 trial initiated August 2020 (New Zealand).

Latest News

  1. SOUTH SAN FRANCISCO, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the company has delivered six poster presentations and an oral presentation at this year's American Association for the Study of Liver Diseases (AASLD) Liver Meeting Digital Experience™ (TLMdX) 2020, held virtually on November 13-16, 2020. The data presented includes updates from three of Aligos' assets in its lead chronic hepatitis B (CHB) combination therapy platform, as well as data from the company's nonalcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC) programs…

    SOUTH SAN FRANCISCO, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the company has delivered six poster presentations and an oral presentation at this year's American Association for the Study of Liver Diseases (AASLD) Liver Meeting Digital Experience™ (TLMdX) 2020, held virtually on November 13-16, 2020. The data presented includes updates from three of Aligos' assets in its lead chronic hepatitis B (CHB) combination therapy platform, as well as data from the company's nonalcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC) programs.

    "We are proud of the progress we have made for the Aligos' liver disease programs as outlined in our presentations during this year's AASLD Liver Meeting," said Lawrence Blatt, Ph.D., MBA, Chief Executive Officer of Aligos. "We are working towards producing a combination regimen of promising therapeutics that have the potential to lead to functional cures for patients living with chronic hepatitis B. Additionally, our team has made substantial progress on ALG-055009, a potent and selective purpose built THR beta agonist for the treatment of NASH. Two of our drug candidates, ALG-010133 (STOPS™) and ALG-000184 (CAM), aimed at the treatment of chronic hepatitis B have already begun Phase 1 clinical trials and we look forward to advancing the remainder of our liver disease portfolio towards clinical development over the coming year."

    Chronic hepatitis B

    Antisense oligonucleotide (ASO)

    Title: Development of a Best-in-Class HBV ASO, ALG-020572, for the Treatment of Chronic Hepatitis B: Potential for Combination with other Anti-HBV Agents

    Authors: Jin Hong, et al.

    Presentation type: Oral presentation

    Summary: Aligos' ASO candidates for chronic hepatitis B significantly improve upon other ASOs in terms of nonclinical safety. ALG-020572, which targets the open reading frame (ORF) of the small HBsAg, demonstrates excellent in vivo potency and safety profiles in an AAV-HBV mouse efficacy model. ALG-020572 or its unconjugated form demonstrated additive to synergistic activity when combined with other anti-HBV agents in vivo or in vitro.

    Capsid assembly modulator (CAM)

    Title: Best-in-class preclinical characteristics of ALG-000184, a prodrug of the capsid assembly modulator ALG-001075 for the treatment of chronic hepatitis B

    Abstract number: 0823

    Presentation type: Poster

    Authors: Andreas Jekle, et al.

    Summary: The in vitro antiviral profile and ADME characteristics of ALG-000184, Aligos' capsid assembly modulator (CAM) candidate for chronic hepatitis B, are described. ALG-001075 is a class-II CAM with broad and potent anti-HBV activity.

    In cell-based assays, both compounds inhibited HBV DNA with nanomolar EC50 values. ALG-001075 had broad antiviral activity against 37 clinical isolates of the hepatitis B virus and retained activity against 6 known CAM resistance mutations, while T33N reduced ALG-001075's antiviral activity 28-fold.

    Oral administration of ALG-000184 in a tablet formulation at doses of 1 to 12.6 mg/kg resulted in complete oral absorption and high exposure to ALG-001075.

    S-antigen Transport-inhibiting Oligonucleotide Polymer (STOPS™)

    Title: ALG-010133, a Representative S-Antigen Transport-inhibiting Oligonucleotide Polymer (STOPS™) Effectively Inhibits Hepatitis B Surface Antigen (HBsAg) Secretion in Multiple Hepatitis B Virus (HBV) Cell Models

    Abstract number: 0821

    Presentation type: Poster

    Authors: Yuchun Nie et al.

    Summary: ALG-010133 demonstrated robust inhibition of HBsAg release in multiple cell lines and infected liver cells across HBV genotypes, with enhanced activity compared to the structurally similar clinical-stage nucleic acid polymer REP-2139. Additionally, intracellular HBsAg was also reduced, suggesting that HBsAg was degraded inside the cell rather than trapped intracellularly.

    ALG-010133 inhibited HBsAg release with the following EC50 values in respective cell models:

    • 3.9 nM in HepG2.2.15
    • 23.7 nM in PLC/PRF 5
    • 3.2 nM in HBV-infected HepG2-NTCP cells
    • 5.9 nM in HBV-infected PHH cells

    Title: The S-Antigen Transport-Inhibiting Oligonucleotide Polymer (STOPS™) ALG-010133 Demonstrates a Favorable Preclinical Profile for the Treatment of Chronic Hepatitis B

    Abstract number: 0831

    Presentation type: Poster

    Authors: Vikrant Gohil, et al.

    Summary: Aligos' STOPS candidate for use in chronic hepatitis B, currently in a Phase 1a/b trial, was evaluated for pharmacokinetic and overall safety profile in nonclinical species through subcutaneous or intravenous dosing.

    Results included the following:

    • 2-week repeat dose studies with weekly SC dosing in nonclinical species showed that ALG-010133 was well tolerated to up to the highest dose tested (50 mg/kg).
    • Rapid uptake and long half-life were demonstrated, with significant recovery in all tissues four weeks after the final dose in nonclinical species.

    NASH

    Title: Characterization of Thyroid Hormone Receptor (THR) Agonists for the Treatment of Non-Alcoholic Steatohepatitis (NASH) by Quantification of Gene Transcription in Human Hepatocytes

    Abstract number: 1665

    Presentation type: Poster

    Authors: Xuan Luong, et al.

    Summary: A fast, high-throughput strategy to rank THR agonist compound efficacy was implemented by using human-derived hepatocytes and quantifying changes in the hepatocytes' transcription of specific genes specific to cholesterol and fatty acid biosynthesis and metabolism directly downstream of THR binding and activation. The ability of three THR agonists to modulate the expression of genes specific to cholesterol and fatty acid biosynthesis and metabolism were compared to one another in vitro and replicated in vivo in a high fat diet-fed rat model for confirmation. Using human-derived hepatocytes provides more biologically relevant data compared to biochemical or non-hepatocyte screening assays.

    Title: ALG-055009, a Potent and Selective THR Beta Agonist for the Treatment of NASH, Demonstrates Significant Cholesterol Reduction in a Diet-Induced Obese (DIO) Mouse Efficacy Model

    Abstract number: 1656

    Presentation type: Poster

    Authors: Kusum Gupta, et al.

    Summary: Aligos' THR-β agonist candidate ALG-055009 in development for NASH is highly efficacious in a diet-induced obese mouse model. With its high and selective potency combined with projected low doses in humans, ALG-055009 has the potential to be a best-in-class THR-β agonist for the treatment of NASH.

    In DIO mouse models, the minimum efficacious dose of 0.15 mg/kg/dose twice daily resulted in 17% and 34% reductions in total and LDL cholesterol, respectively. None of the doses induced any significant changes in gene expression in the heart, indicating a potentially wide safety margin.

    Hepatocellular carcinoma

    Title: Tumor Regression in a Mouse Model of Hepatocellular Carcinoma Upon Treatment with the STING Agonist ALG-031048

    Abstract number: 1118

    Authors: Andreas Jekle, et al.

    Summary: Aligos' novel STING agonist ALG-031048 was evaluated in the Hepa1-6 HCC mouse model, for potential use in the treatment of advanced hepatocellular carcinoma.

    Three intratumorally administrated doses of ALG-031048 induced robust dose-dependent anti-tumor activity, resulting in an average 14% tumor reduction (TR) at 25 μg dosing, with tumor regression achieved in 7 of 10 mice; and 88% tumor regression at 100 μg dosing, with tumor regression achieved in all 10 mice. Both were an improvement over single agent anti-PD-1 treatment.

    After intratumoral and subcutaneous administration in CT26 and MC38-hPD-L1 murine models of colon carcinoma, ALG-031048 showed strong anti-tumor activity, which was augmented in combination with antibodies against the immune checkpoint inhibitor CTLA-4 in the CT26 model or in combination with the anti-PD-L1 antibody, atezolizumab, in the MC38-hPD-L1 model.

    About Aligos

    Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos' strategy is to harness the deep expertise and decades of drug development experience its workforce has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.

    Forward Looking Statements

    This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered "forward-looking statements," Including without limitation statements regarding our working towards producing a combination regimen of therapeutics that may lead to functional cures for patients living with CHB and our looking forward to advancing the remainder of our liver disease portfolio towards clinical development over the coming year. Forward-looking statements are typically, but not always, identified by the use of words such as "may," "will," "would," "believe," "intend," "plan," "anticipate," "estimate," "expect," and other similar terminology indicating future results. Such forward-looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include without limitation risks and uncertainties inherent in the drug development process, including Aligos's clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, Aligos's ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of Aligos's capital resources to fund operations, reliance on third parties for manufacturing and development efforts, changes in the competitive landscape and the effects on our business of the worldwide COVID-19 pandemic. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos's prospectus filed with the Securities and Exchange Commission on October 19, 2020, and its future periodic reports to be filed with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.

    Media Contact

    Amy Jobe, Ph.D.

    LifeSci Communications

    +1 315 879 8192

    Investor Contact

    Corey Davis, Ph.D.

    LifeSci Advisors

    +1 212 915 2577



    Primary Logo

    View Full Article Hide Full Article
  2. SOUTH SAN FRANCISCO, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that management will be participating in two upcoming virtual investor conferences and invites investors to participate by webcast. Please see additional details below:

    • Jefferies 2020 Virtual London Healthcare Conference, November 17-19, 2020
      Management will deliver a company presentation on Thursday, November 19 at 10:50 a.m. ET (3:50 p.m. GMT) and will also be available for one-on-one meetings. A live and archived webcast of the presentation will be available on the Investors…

    SOUTH SAN FRANCISCO, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that management will be participating in two upcoming virtual investor conferences and invites investors to participate by webcast. Please see additional details below:

    • Jefferies 2020 Virtual London Healthcare Conference, November 17-19, 2020

      Management will deliver a company presentation on Thursday, November 19 at 10:50 a.m. ET (3:50 p.m. GMT) and will also be available for one-on-one meetings. A live and archived webcast of the presentation will be available on the Investors section of the Aligos website: https://investor.aligos.com
    • Piper Sandler 32nd Annual Virtual Healthcare Conference, December 1-3, 2020

      Management will present in a fireside chat format and will be available for one-on-one meetings. The presentations will be available prior to the dates of the conference. A replay of the fireside chat will be available in the Investors section of the Aligos website: https://investor.aligos.com

    About Aligos

    Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos' strategy is to harness the deep expertise and decades of drug development experience its workforce has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.

    Please visit www.aligos.com for more information.

    Forward Looking Statements

    This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered "forward-looking statements." Forward-looking statements are typically, but not always, identified by the use of words such as "may," "will," "would," "believe," "intend," "plan," "anticipate," "estimate," "expect," and other similar terminology indicating future results. Such forward-looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include without limitation risks and uncertainties inherent in the drug development process, including Aligos's clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, Aligos's ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of Aligos's capital resources to fund operations, reliance on third parties for manufacturing and development efforts, changes in the competitive landscape and the effects on our business of the worldwide COVID-19 pandemic. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos's prospectus filed with the Securities and Exchange Commission on October 19, 2020, and its future periodic reports to be filed with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.

    Media Contact

    Amy Jobe, Ph.D.

    LifeSci Communications

    +1 315 879 8192

    Investor Contact

    Corey Davis, Ph.D.

    LifeSci Advisors

    +1 212 915 2577



    Primary Logo

    View Full Article Hide Full Article
  3. SOUTH SAN FRANCISCO, Calif. and LEUVEN, Belgium, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that its Belgian subsidiary Aligos Belgium BV has been awarded a €1.8M grant by the Flemish Agency for Innovation and Entrepreneurship (VLAIO) to support a nonclinical research project related to combination therapy for Hepatitis B at Aligos (CoHeBA).

    "CoHeBA aims to elucidate the mechanism of action of the therapeutic candidates for chronic hepatitis B (CHB) currently in development at Aligos," said Yannick Debing, Ph.D., principal scientist and lead on the project…

    SOUTH SAN FRANCISCO, Calif. and LEUVEN, Belgium, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that its Belgian subsidiary Aligos Belgium BV has been awarded a €1.8M grant by the Flemish Agency for Innovation and Entrepreneurship (VLAIO) to support a nonclinical research project related to combination therapy for Hepatitis B at Aligos (CoHeBA).

    "CoHeBA aims to elucidate the mechanism of action of the therapeutic candidates for chronic hepatitis B (CHB) currently in development at Aligos," said Yannick Debing, Ph.D., principal scientist and lead on the project application. "The support from VLAIO will allow us to collaborate with some of the most esteemed leaders in the hepatitis B field to identify how Aligos' CHB assets target components of the hepatitis B virus life cycle. Developing a greater understanding of the candidates' mechanism of action will empower our scientific team to develop pharmacologically best-in-class therapies."

    The three-year project will include collaborations with the laboratories of Prof. Jan Paeshuyse (KU Leuven, Belgium), Profs. Stephen Locarnini and Hans Netter (VIDRL, Melbourne, Australia), Profs. Patrick Kennedy and Upkar Gill (Queen Mary University London, United Kingdom), and Profs. Thomas Baumert and Eloi Verrier (INSERM U1110, University of Strasbourg, France).

    "Our team at Aligos Belgium BV contributes greatly to our success in discovering potential therapies for an infection that affects hundreds of millions of people, increasing their risk of end-stage liver disease," said Lawrence Blatt, Ph.D., MBA, Chief Executive Officer of Aligos. "We expect that the outcomes of this project will help us design the most promising combination therapies and next-generation therapeutics for those patients."

    About Chronic Hepatitis B (CHB)

    CHB is a major cause of chronic liver disease that affects over 290 million people worldwide. Serious complications of CHB include cirrhosis and liver cancer, which are associated with significant mortality. Approximately 900,000 people died from CHB-related causes in 2015 alone and the mortality rate associated with HBV-related liver cancer continues to increase. Although current standard of care for patients with CHB is effective in suppressing HBV, it is associated with very low rates of functional cure, which is the goal for future CHB treatments.

    About Aligos

    Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos' strategy is to harness the deep expertise and decades of drug development experience its workforce has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.

    About the Agency for Innovation & Entrepreneurship

    (Agentschap Innoveren & Ondernemen, VLAIO)www.vlaio.be

    This project is supported by the Agency for Innovation & Entrepreneurship, the point of contact of the Flemish Government for all entrepreneurs in Flanders. VLAIO stimulates and supports innovation and entrepreneurship and contributes to a favorable entrepreneurial climate, in collaboration with many partners.

    Forward Looking Statements

    This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered "forward-looking statements," including without limitation statements regarding Aligos's expectations that the outcomes of the CoHebA project will enable Aligos' development of next generation, pharmacologically best-in-class therapies and Aligos' design of combination therapies. Forward-looking statements are typically, but not always, identified by the use of words such as "may," "will," "would," "believe," "intend," "plan," "anticipate," "estimate," "expect," and other similar terminology indicating future results. Such forward-looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include without limitation risks and uncertainties inherent in the drug development process, including Aligos's clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, Aligos's ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of Aligos's capital resources to fund operations, reliance on third parties for manufacturing and development efforts, changes in the competitive landscape and the effects on our business of the worldwide COVID-19 pandemic. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos's prospectus filed with the Securities and Exchange Commission on October 19, 2020, and its future periodic reports to be filed with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.

    Media Contact

    Amy Jobe, Ph.D.

    LifeSci Communications

    +1 315 879 8192

    Investor Contact

    Corey Davis, Ph.D.

    LifeSci Advisors

    +1 212 915 2577

     

    Primary Logo

    View Full Article Hide Full Article
  4. SOUTH SAN FRANCISCO, Calif., Oct. 30, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that it has dosed its first subject in a first-in-human Phase 1a/b clinical trial, ALG-000184-201 (NCT04536337). The study will evaluate ALG-000184, a small molecule class II capsid assembly modulator (CAM) that targets hepatitis B virus (HBV) capsid assembly as well as the establishment of covalently closed circular DNA (cccDNA).

    "We are excited to advance ALG-000184 into clinical studies," said Lawrence Blatt, Ph.D., MBA, Chief Executive Officer of Aligos. "In collaboration with…

    SOUTH SAN FRANCISCO, Calif., Oct. 30, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that it has dosed its first subject in a first-in-human Phase 1a/b clinical trial, ALG-000184-201 (NCT04536337). The study will evaluate ALG-000184, a small molecule class II capsid assembly modulator (CAM) that targets hepatitis B virus (HBV) capsid assembly as well as the establishment of covalently closed circular DNA (cccDNA).

    "We are excited to advance ALG-000184 into clinical studies," said Lawrence Blatt, Ph.D., MBA, Chief Executive Officer of Aligos. "In collaboration with Dr. Raymond Schinazi's laboratory at Emory University, our experienced discovery and development team has optimized ALG-000184 to have best-in-class pharmacological potential. We look forward to learning how these optimized drug properties may translate into benefits for patients living with chronic hepatitis B."

    Matthew W. McClure, M.D., Chief Medical Officer at Aligos, noted, "ALG-000184-201 is a multipart Phase 1a/1b umbrella trial that will evaluate the safety and pharmacokinetics of single and multiple ascending doses of ALG-000184 in healthy volunteers, and the antiviral activity of ALG-000184 given once-daily over 28 days in patients with chronic hepatitis B (CHB). This is Aligos' second CHB drug candidate to enter the clinic this year and we expect the 201 study will provide important proof of concept data related to the antiviral activity of ALG-000184. We look forward to sharing initial topline results from this study in the second half of 2021."

    ALG-000184 is one of several drug candidates in Aligos' chronic hepatitis B (CHB) portfolio, which targets different clinically validated mechanisms of action in the HBV life cycle. The portfolio also includes: ALG-010133, a S-antigen Transport-inhibiting Oligonucleotide Polymers (STOPSTM) molecule, which entered clinical development earlier this year; ALG-020572, an antisense oligonucleotide (ASO); and ALG125097, a small interfering RNA (siRNA). Initially, Aligos plans to evaluate the antiviral activity of each of these drug candidates individually in Phase 1 umbrella trials before evaluating them in combination in subsequent trials.

    About Aligos

    Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos' strategy is to harness the deep expertise and decades of drug development experience its workforce has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.

    Forward Looking Statements

    This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered "forward-looking statements," including without limitation statements regarding Aligos's expectations that the 201 study will provide important proof of concept data related to the antiviral activity of ALG-000184, the timing of initial topline results from the 201 study, and Aligos's clinical development plans for the drug candidates in its portfolio. Forward-looking statements are typically, but not always, identified by the use of words such as "may," "will," "would," "believe," "intend," "plan," "anticipate," "estimate," "expect," and other similar terminology indicating future results. Such forward-looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include without limitation risks and uncertainties inherent in the drug development process, including Aligos's clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, Aligos's ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of Aligos's capital resources to fund operations, reliance on third parties for manufacturing and development efforts, changes in the competitive landscape and the effects on our business of the worldwide COVID-19 pandemic. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos's prospectus filed with the Securities and Exchange Commission on October 19, 2020, and its future periodic reports to be filed with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.

    Media Contact

    Amy Jobe, Ph.D.

    LifeSci Communications

    +1 315 879 8192



    Investor Contact

    Corey Davis, Ph.D.

    LifeSci Advisors

    +1 212 915 2577



    Primary Logo

    View Full Article Hide Full Article
View All Aligos Therapeutics Inc. News